Claims Review Before Creative Ships: Who Signs Off and How Fast

Who holds sign-off authority when there is no legal department?

One person signs off, named by title not by department, and the buck stops there. In a five-person shop that is the founder; past ten heads it is usually the senior buyer or the head of creative, someone who has read every VSL script this month and already knows which claims got flagged before. A committee dilutes the decision until nobody owns it. Naming one person, plus a backup for vacations, is most of the org chart a testing operation needs before its first ad goes live.

The reviewer's job is narrower than "legal," which matters because most shops confuse the two. Networks already publish what they expect from an internal gate, and the logic lines up with why affiliate networks demand compliance sign-off before they will run a creative at all: a named approver, a dated record, a clear no. Borrowing that structure internally means the reviewer checks against the same list a network's own compliance team applies later, not a separate standard invented in-house.

Give the reviewer real veto power over a launch, not advisory input a buyer can override on a busy Friday. If the person holding sign-off cannot stop a script from shipping, the role is decorative. Put the authority in writing once, so the question never gets re-litigated mid-launch.

What does the reviewer actually check, line by line, on a VSL script or advertorial?

The reviewer checks five things every time: the disclaimer, the performance claims, the allergen language, the contact information, and whether the ad's claim matches what the product itself can support. Where a structure/function claim appears, 21 CFR 101.93, as reproduced by Cornell's Legal Information Institute, requires the exact boilerplate — "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease" — set in boldface next to the claim with nothing wedged between them.

The reviewer also reads for the gap between what the ad promises and what the label or checkout page actually says, because that mismatch is where insurance coverage disappears if a false-advertising claim ever lands. Standard commercial general liability language excludes injury arising from a product's failure to conform with a statement of quality or performance made in an advertisement, wording that turns up verbatim in eleven published opinions found through a CourtListener search of the exact phrase — so an ad and a label that disagree is a compliance problem before it is an insurance problem.

• Every disease-adjacent phrase gets flagged and either cut or paired with the FDA disclaimer described above.
• Every "contains" allergen statement matches the ingredient list, since federal law recognizes nine major allergens including sesame.
• Every claim is attributed to the VSL itself — "the VSL claims," never "the product does" — with the attribution sitting in the same sentence as the claim.
• Every script gets checked against what a rival is currently running, which is most of the reason a research pass on [competitor VSLs](/markets/hotmart-producers-research-rival-vsls-before-launch) happens before a new angle ships rather than after.
• Every income or earnings phrase gets deleted outright, no exceptions.

How do you review at the pace creative testing demands?

Speed comes from a checklist run in minutes, not a debate run in days, and the checklist has to already exist before the script lands in the reviewer's inbox. A shop testing six new angles a week cannot afford a reviewer who re-derives the disease-claim line from scratch every time. Write the five checks down once, keep them on one page, and review becomes reading against a list rather than reasoning from principles under deadline pressure.

Batch review by angle, not by asset. Once a hook and its supporting claims clear, the ten thumbnail and headline variants a buyer wants tested against that same hook do not each need a fresh legal read; they need a fast confirm that nothing new got added. Reserving full review time for genuinely new claims, and five-minute confirms for variants of an already-cleared angle, is what keeps testing velocity and same-day answers on most submissions.

Tools that show you what is already running elsewhere shorten the review too. A reviewer checking a new angle against a documented library of live rival creative can flag a copycat disease claim in the time it takes to open the tool, rather than researching the claim's history from nothing.

What gets escalated to outside counsel, and what does one review cost?

Escalate three things to outside counsel: a claim edging toward disease treatment, a new ingredient with no prior market history, and any script written after the company has already received an FTC inquiry or order. Routine angle variations, price framing and standard structure/function language stay inside the shop. What one outside review actually costs varies by firm and by claim complexity, and no verified hourly rate for supplement or direct-response ad counsel turned up in this pass, so treat any figure under a few hundred dollars an hour as optimistic until confirmed with the firm retained.

The instinct to insure against a bad claim getting through is often overconfidence, because standard commercial general liability policies exclude exactly the failure mode a direct-response brand fears most: harm from a product's failure to conform with what its own advertisement claimed. Media liability insurance, per Founder Shield's description of the product, is the closer analogue, covering false-advertising representations alongside copyright, trademark and defamation exposure, but it excludes bodily injury, breach of contract and criminal acts, and the claims-made retro-date mechanics that decide whether an older claim is even covered were not confirmed on the broker page reviewed here — check that against an actual specimen policy before counting on it.

Regulatory cost runs on a different meter than insurance anyway. Civil penalties for a knowing violation of an FTC rule on unfair or deceptive acts can reach $53,088 per violation, per the Federal Register's January 2025 adjustment of FTC penalty amounts, and the Supreme Court's 2021 ruling in AMG Capital Management v. FTC stripped the agency of its old shortcut to restitution and disgorgement under section 13(b). What remains runs through penalties and section 19 redress, categories most liability policies are not built to absorb — the real argument for a tight internal review is that no policy reliably pays for what a bad claim actually costs.

How do you version and archive an approved creative so you can prove what ran?

Archive every approved asset with four things attached: the exact copy that ran, the date it went live, who signed off, and the date it got pulled. A version number alone proves nothing if nobody can also produce the sign-off record next to it — that pairing is what turns an archive into evidence rather than a folder of old ad copy.

No statute sets a retention clock specifically for ad creative archives. Borrowing a number from an adjacent recordkeeping duty is reasonable practice, not a legal requirement: the responsible person for a labeled supplement product must keep serious-adverse-event records for six years under 21 U.S.C. 379aa-1, and treating that as a floor for a creative archive is a sane default even though nothing requires it for advertising specifically. How long a given angle stays worth keeping also depends on how fast it burns — a market where creative lifespan runs shorter still needs the same proof-of-approval discipline, just recycled more often.

What happens when a buyer ships an unapproved variant anyway?

The campaign gets pulled the moment anyone notices, and the incident goes into the same log as an approved launch, not a separate quiet conversation. Treating an unapproved variant as a minor scheduling issue undersells what's actually at stake: the company's name carries the exposure, not the individual buyer's.

That principle already exists in adjacent regulation and it transfers cleanly. FDA's preamble to the dietary supplement manufacturing rule, published in the Federal Register at 72 FR 34752, states a brand is responsible for a contracted party's work "no different than a quality control operation performed by your employees," and that responsibility does not shift because the actual work happened somewhere else. A media buyer who ships a rogue claim is the ad-industry version of that contractor — the brand answers for it regardless of who typed the script.

Make the consequence real before it happens once: a first unapproved launch gets pulled and logged, a second costs that buyer sign-off privileges on future scripts, and the reviewer's authority to pull an ad without asking permission first has to survive contact with an angry media buyer on a good sales day.

How do you review UGC and affiliate-made creative you did not write?

Review it exactly like in-house copy, because the label on the offer, not the identity of who wrote the script, determines whose name carries the liability. FDA's Part 111 preamble puts the underlying logic plainly: a distributor who contracts out manufacturing still has an obligation to "know what and how manufacturing activities are performed" well enough to approve or reject what comes back. The same logic applies to a script an affiliate or a UGC creator hands you — reading it before it runs is the brand's job, not theirs.

Affiliates move faster than employees and often push variants that never touch the reviewer at all, which is the real risk, not the writing quality. Platforms that auto-generate creative variations raise the identical question at a different layer — whether to trust an automated system's edits the way you would trust Advantage+ creative enhancements without a human second look — and the answer for affiliate content is the same as the answer for an algorithm: nothing ships to the account's own ad library without the same five-point check applied to everything else.

Set the rule with the affiliate in writing before the first payout, not after the first violation. A revenue-share relationship does not change who a network or a regulator holds accountable for the claim on the ad.

What does the review log do for you when a network or a regulator asks?

It turns "we were careful" into a dated, named record instead of an assertion nobody can check. A regulator or a network compliance team does not want intentions; it wants the sign-off record, the date the asset went live, and the version that actually ran, produced in minutes rather than reconstructed from memory under deadline pressure.

The habit already has a model in adjacent enforcement practice. Under 21 CFR 7.46, a firm handling a suspect food product has to hand FDA the product's identity, the reason for the issue, a risk evaluation and a named responsible contact the moment it decides to act, not after an investigator asks for it. A review log that already contains the equivalent information for a creative — which claim, who cleared it, when it stopped running — puts the operation in the same position as a firm that walks into an inquiry with its paperwork already assembled.

It also matters to whoever underwrites your risk. Media liability coverage is written on a claims-made basis in the broker material Founder Shield publishes, though the retro-date mechanics were not confirmed on that page, and an insurer asking when a claim was first made gets a real answer only if the log already has the date attached. A log built after the fact does not help either the regulator or the underwriter.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Same Sale, Three Positions: What CPA, Rev Share, and Ownership Each Pay, What Actually Determines the Number: Seven Variables Behind DR Income, When Hiring a Second Buyer Pays: The Economics of a Small Media Team, Four Ways an Offer Dies: Reading the Death Certificate in Public Data, What is a VSL?, and UTM parameter decoding guide. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.